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Summary We have analysed 174 gastric carcinomas from the United Kingdom and from Japan for the
presence of Epstein-Barr virus (EBV) using in situ hybridisation for the small EBV-encoded nuclear RNAs
(EBERs). EBV was detected in the tumour cells in all of six undifferentiated gastric carcinomas with
prominent lymphoid stroma (undifferentiated carcinomas of nasopharyngeal type, UCNT) but only in three of
the remaining 168 typical gastric adenocarcinomas (1.8%). No differences were observed between the British
and the Japanese cases. One case with an EBV-positive UCNT showed adjacent areas of EBV-negative typical
adenocarcinoma. It is uncertain whether these patterns represent two independent carcinomas or whether they
are the result of heterogenous EBV infection in a single tumour. In the remaining EBV-positive carcinomas,
viral transcripts were detected in virtually all tumour cells, indicating that EBV infection must have taken
place early in the neoplastic process and suggesting that the virus is likely to be of pathogenetic significance for
the virus-associated tumours. Immunohistology demonstrated absence of detectable levels of the EBV-encoded
latent membrane protein, LMPI, and nuclear antigen, EBNA2. The BZLFI protein which induces the switch
from latent to lytic infection was demonstrated in a small proportion of the tumour cells in three cases. The
close association of EBV with undifferentiated gastric carcinomas compared to the variable association with
gastric adenocarcinomas suggests fundamentally different roles for the virus in the aetiology of these two
malignancies.
The Epstein-Barr virus (EBV) is well known for its associa-
tion with several human malignancies such as Burkitt's lym-
phoma (BL) and Hodgkin's disease (HD) (Herbst et al.,
1991; Herbst et al., 1993; Miller, 1990a; Zur Hausen et al.,
1970). However, the tumour showing world wide the
strongest association with the virus is an epithelial neoplasm,
undifferentiated nasopharyngeal carcinoma (NPC) (Klein,
1979). Undifferentiated NPC is endemic in certain geographic
areas, e.g. Southern China and North Africa, while it occurs
only sporadically in Western Europe and North America
(Klein, 1979). However, EBV DNA is detected in virtually all
cases regardless of geographic origin (Klein, 1979). The small
EBV-encoded nuclear RNAs (EBERs) are expressed in all
EBV-positive cases (Niedobitek et al., 1992b; Wu et al.,
1991), and the transformation-associated protein of EBV,
latent membrane protein 1 (LMP1), is detectable in a propor-
tion of cases (Fahraeus et al., 1988; Niedobitek et al., 1992b;
Young et al., 1988).
In the nasopharynx, EBV appears to be associated exclus-
ively with undifferentiated carcinomas but not with
squamous cell carcinomas (Klein et al., 1974; Klein, 1979;
Niedobitek et al., 1991a; 1993a). Undifferentiated NPC dis-
play a number of characteristic morphological features, in-
cluding a prominent lymphoid stroma which is seen in most
cases. In recent years, carcinomas with similar morphological
features (undifferentiated carcinomas of nasopharyngeal type,
UCNT) from other anatomical sites have been analysed for
the presence of EBV. These studies have led to the
identification of a new EBV-associated tumour entity, gastric
UCNT (Burke et al., 1990; Min et al., 1991; Niedobitek et
al., 1992a; Shibata et al., 1991; Watanabe et al., 1976).
Although the total number of cases studied is low, the
available evidence suggests a similarly strong association of
gastric UCNT with EBV as seen with undifferentiated NPC.
Also, cases from different geographic areas appear to be
invariably EBV positive (Burke et al., 1990; Min et al., 1991;
Niedobitek et al., 1992a; Shibata et al., 1991). More recently,
a study from the USA has also reported expression of the
EBER transcripts in the tumour cells of 16% of classical
gastric adenocarcinomas (Shibata & Weiss, 1992).
We have analysed a large series of gastric carcinomas
comprising cases from the United Kingdom and from Japan
for the presence of EBV using in situ hybridisation for the
detection of the EBER transcripts. EBV positive cases were
further studied by immunohistology with monoclonal
antibodies for the detection of latent and replicative viral
antigens.
Materials and methods
Tissues
Formalin-fixed and paraffin-embedded tissue samples from
174 gastric carcinomas obtained from resection specimens
were studied. 120 cases were from Birmingham, UK, and 54
specimens were from Nagoya, Japan. The Japanese cases
included three cases specifically selected for their NPC-like
morphological features. The age range of the UK cases was
from 35 years to 87 years with a mean age of 66 years. The
male-to-female ratio of the British cases was 2.03. The age
range of the Japanese cases was from 33 years to 84 years
with a mean age of 63 years. The male-to-female ratio of the
Japanese cases was 1.17. The pathological characteristics of
the cases are summarised in Table I. Paraffin blocks of an
EBV-induced lymphoma arising in a cottontop tamarin were
kindly provided by Dr A. Morgan and S. Finerty, University
of Bristol, Bristol, UK.
In situ hybridisation
Digoxigenin- or 35S-labelled RNA probes were generated by
in vitro transcription from the plasmids pBSJJJI and pBSJJJ2
harbouring EBER1- and EBER2-specific inserts, respectively
(Niedobitek et al., 1991b). To increase sensitivity, antisense
probes derived from the two plasmids were mixed. Likewise,
the two sense control probes were mixed. Prehybridisation
treatment of tissue sections, hybridisation conditions and
posthybridisation washes were as described previously
(Niedobitek et al., 1991b; Niedobitek et al., 1993a). All cases
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Table I Summary of pathological data
Birmingham cases Nagaoya cases Total cases
Total 120 54 174
Site
Cardia 44 20 64
Corpus/Antrum 75 32 107
Unknown 1 2 3
Stage
EGC 10 17 27
AGC 110 37 147
Lauren type
Intestinal 55 26 81
Diffuse 26 18 44
Mixed 25 3 28
Unclassifieda 14 7 21
Abbreviations: EGC =early gastric carcinoma (primary tumour
limited to mucosa and/or submucosa); AGC = advanced gastric
carcinoma (tumour in muscularis propria or beyond). aSix of these
cases were UCNT, extensive areas showing a diffuse pattern were
seen in one of these cases.
from the United Kingdom were also hybridised to a 35S-
labelled kappa immunoglobulin light chain-specific RNA
probe (550 bp SstI fragment containing the human Ig kappa
gene constant segment, kindly provided by Dr P. Leder,
Cambridge, Massachussets, Hieter et al., 1980). Immobilised
digoxigenin-labelled probe was detected using a digoxigenin-
specific mouse monoclonal antibody and conventional
immunohistology using the alkaline phosphatase-anti-alkaline
phosphatase (APAAP) method (Niedobitek et al., 1993a).
35S-labelled probe was detected by autoradiographic techni-
ques using Ilford G5 emulsion as described previously
(Niedobitek et al., 1991b).
Immunohistology
The monoclonal antibodies, CS1-4, specific for LMPI
(Rowe et al., 1987), PE-2, directed against the EBV-encoded
nuclear antigen, EBNA2 (Young et al., 1989a), and BZ-1,
specific for the BZLF1 protein (Young et al., 1991) were
obtained from Dakopatts, Glostrup, Denmark. Before ap-
plication of the primary antibodies and APAAP immunohis-
tochemistry, paraffin sections were exposed to microwave
irradiation in 0.01 M citrate buffer, pH 6, for 40 min. This
pre-treatment was shown to improve staining with the
CSl-4 reagent, and to render the EBNA2 and BZLF1 pro-
teins detectable in paraffin sections (unpublished observa-
tion).
Results
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Figure 1 In situ hybridisation with digoxigenin-labelled probes
reveals expression of the EBER transcripts in the tumour cell
nuclei of a, an undifferentiated gastric carcinoma, b, a diffuse
gastric carcinoma, and c, an intestinal gastric carcinoma
(haematoxylin counterstaining, bar represents 50 lm).
In situ hybridisation revealed expression of the EBER tran-
scripts in the tumour cell nuclei of all of six UCNT and in
three of 168 (1.8%) typical gastric adenocarcinomas (Table
II). Five of the patients with EBV-positive carcinomas were
male and two were female. The age range of the EBV-
positive cases was between 37 and 73 years, with a medium
age of 50.6 years. Five of the patients were from the United
Kingdom and four were from Japan. Five of the EBV-
positive carcinomas were located in the corpus/antrum
region, four cases originated at the cardia. Histologically,
two of the cases were pure UCNT without any evidence of
glandular or other differentiation (Figure la). Four cases
showed predominantly features of UCNT but minor areas of
glandular differentiation were also seen. Three EBV-positive
cases showed the histological characteristics of typical gastric
adenocarcinomas; one was a largely intramucosal carcinoma
of intestinal type and two were mixed carcinomas showing
features of both diffuse and intestinal tumours (Figure lb, c).
All UCNT had a prominent lymphoid stroma over most of
their extent but areas lacking this feature were observed in
one case. The EBV-positive intramucosal intestinal car-
cinoma showed large numbers of lymphoid cells between the
neoplastic glands. However, their number did not exceed that
of the lymphoid cells seen in the surrounding non-neoplastic
mucosa showing a chronic gastritis. Of the two EBV-positive
mixed carcinomas, one showed a prominent lymphoid
stroma, the other lacked this feature. In eight of the nine
EBV-positive cases, the vast majority of tumour cells were
labelled. However, the staining intensity varied within any
given case, and in some cases a small proportion of tumour
cells appeared unstained. Weaker labelling of tumour cells
was observed predominantly in areas showing glandular
differentiation. One case (case 9 in Table II) showed areas of
UCNT with lymphoid stroma immediately adjacent to areas
with adenocarcinoma lacking a lymphoid stroma. In situ
hybridisation revealed uniform expression of the EBER
transcripts in virtually all tumour cells in those areas display-
ing UCNT morphology (Figure 2a). By contrast, there was
no evidence of EBV infection in areas with classical gastric
carcinoma (Figure 2b).
All available blocks of the five cases from Birmingham
were analysed by EBER in situ hybridisation. Consistent1016 D.C. ROWLANDS et al.
Table II Summary of EBV-positive gastric carcinomas
Casea Type Site EBER LMPJ EBNA2 BZLFI
1 UCNT Co/A + - - -
2 Mixed Ca + - -
3 UCNT Co/A + - - -
4 UCNT Co/A + - - +sc
5 Mixed Co/A + - - +sc
6 UCNT Ca + - - nd
7 UCNT Co/A + - nd
8 Intestinal Ca + - nd
9 UCNT Ca + - - +sc
Abbreviations: UCNT = undifferentiated carcinoma of nasopharyngeal
type; Co/A = corpus/antrum; Ca = cardia; sc = scattered; nd = not done.
aCases 1 to 5 were from Birmingham, cases 6 to 9 were from Nagoya.
a b
Figure 2 A case showing a gastric UCNT and adjacent areas of a typical adenocarcinoma (case 9 in Table II); in situ hybridisation
with non-radioactive probes demonstrates expression of the EBER transcripts in the UCNT a, but not in the typical gastric
carcinoma areas b, of this case (no counterstaining, bar represents 50pm).
expression of the EBER transcripts was demonstrated in all
tumour samples. Metastatic tumour deposits found in two of
the cases were also EBV-positive. No EBV-specific signal was
observed in multiple samples of non-neoplastic mucosa of
any of the nine EBV-positive cases, nor in the non-neoplastic
mucosa which was present in almost all of the other cases
(not shown).
Integrity of RNA was assessed by two approaches. All
cases from the United Kingdom were hybridised to a kappa
immunoglobulin light chain-specific probe. A clear signal was
obtained in all cases over plasma cells after short exposure
(not shown). Furthermore, EBV-negative cases which had
been hybridised to the 35S-labelled EBER probes were
examined for the presence of EBV-infected lymphocytes.
Variable but usually small numbers of EBER-positive lym-
phocytes were detected in 40 of 80 cases from Birmingham
and in ten of 21 cases from Nagoya (not shown). Sections
hybridised to digoxigenin-labelled EBER probes were not
taken into consideration in this respect because of the lower
sensitivity of these probes (unpublished observation). How-
ever, both radioactive and non-radioactive probes were
equally suited for the detection of the EBERs in the tumour
cells, presumably due to increased expression of the EBERs
in the tumour cell environment. No signal was detected in
any of the cases using the sense control probes.
Immunohistological analysis of paraffin sections revealed
expression of the LMP1, EBNA2, and BZLF-I proteins of
EBV in varying proportions of an EBV-induced lymphoma
arising in a cottontop tamarin (not shown). By contrast, only
the BZLF1 protein was detectable in a very small proportion
of the tumour cells of three EBV-associated gastric car-
cinomas (Figure 3) while LMP1 and EBNA2 were not detec-
table. Two of the carcinomas with BZLFl-positive tumour
cells were UCNT, 1 was an adenocarcinoma of mixed
type.
Discussion
EBV has long been known to be associated with
nasopharyngeal carcinomas (Klein, 1979). EBV DNA and
viral gene products are detectable in virtually all cases of
undifferentiated NPC, but not in squamous cell carcinomas
of the same site (Klein et al., 1974; Klein, 1979; Niedobitek
et al., 1991a; Niedobitek et al., 1993a; Zur Hausen et al.,
1970). Studies addressing the possible association of EBV
with carcinomas arising outside the nasopharynx have dem-
onstrated the presence of EBV DNA in salivary gland
UCNT in Greenland Eskimos but not in Danish Caucasians
(Hamilton-Dutoit et al., 1991). Furthermore, several reports
have suggested the possibility of an association of gastric
UCNT with EBV (Burke et al., 1990; Min et al., 1991;
Niedobitek et al., 1992a; Shibata et al., 1991). In this study,
expression of the EBER transcripts was observed in all of six
gastric UCNT. Three of these cases were from Japan and
three were from the United Kingdom. Thus, our results
further support the observation that gastric UCNT are
closely associated with EBV and, in conjunction with other
studies, suggest that, like undifferentiated NPC, these
tumours are EBV-positive in all geographic regions. More
recently, Shibata and Weiss (1992) have reported the
presence of EBV also in 16% of typical gastric adenocar-EBV IN GASTRIC CARCINOMAS 1017
Figure 3 Expression of the BZLF1 protein of EBV in an
isolated tumour cell nucleus (arrow) of a gastric carcinoma is
demonstrated by immunohistology (APAAP, haematoxylin
counterstaining, bar represents 50 tm).
cinomas from the USA. This observation was surprising
because previous evidence had suggested an association of
EBV exclusively with undifferentiated carcinomas
(Niedobitek et al., 1993b). Here we demonstrate expression
of the EBER transcripts in three of 168 gastric adenocar-
cinomas (1.8%), indicating latent EBV infection in the
tumour cells. The difference between our results and the 16%
incidence of EBV-positive gastric adenocarcinomas reported
by Shibata and Weiss (1992) is difficult to explain. RNA
integrity was confirmed by in situ hybridisation to a kappa
immunoglobulin light chain-specific probe in all cases from
Birmingham. Furthermore, EBV-positive small lymphocytes
were detected in approximately 50% of carcinomas with
EBV-negative tumour cells from Birmingham and from
Nagoya. Thus RNA degradation is unlikely to have contri-
buted to the high rate of EBV-negative tumours in our
series.
Whilst undifferentiated NPC occurs with varying frequency
in different geographic areas, all cases are invariably
associated with the virus. However, other tumours, most
notably Burkitt's lymphoma, are known for their invariable
association with EBV only in certain regions (Miller, 1990a).
Therefore, the possibility of geographic variation in the EBV-
association of gastric adenocarcinomas was examined in this
study by comparing cases from the United Kingdom and
from Japan. In both series, not more than 2% of the
tumours were EBV-positive, thus excluding major differences
between these two regions. It appears therefore, that EBV is
not a major aetiological agent in the development of gastric
adenocarcinomas in Western Europe and Japan. However, in
view of the report by Shibata and Weiss (1992), the pos-
sibility of epidemiological differences between these two
regions and the USA remains and requires further investiga-
tion. Shibata and Weiss (1992) also reported an almost ex-
clusive association of EBV with adenocarcinomas in male
patients. Whilst a predominance of male patients amongst
the EBV-positive cases was also found in our study, the
numbers appear too small to draw any firm conclusions.
Immunohistological analysis of the EBV-positive cases
revealed the absence of detectable levels of the EBNA2 and
LMP1 proteins of EBV. These data are in line with previous
reports demonstrating the consistent lack of EBNA2 expres-
sion in EBV-associated carcinomas (Fahraeus et al., 1988;
Niedobitek et al., 1992b; Young et al., 1988). By contrast, we
and others have demonstrated that between 20 and 60% of
undifferentiated NPC show detectable levels of LMP1 expres-
sion (Fahraeus et al., 1988; Niedobitek et al., 1992a; Young
et al., 1988). Thus, the absence of this viral protein from all 9
EBV-positive gastric carcinomas is unexpected. However,
more cases and preferably snap frozen material will have to
be analysed to clarify this point. Expression of the BZLF1
transactivator protein of EBV in a small proportion of
tumour cells was demonstrated in three of nine EBV-positive
carcinomas. Two of these were UCNT, one was an adenocar-
cinoma of mixed type. The BZLF1 protein is an early viral
protein disrupting EBV latency in B lymphocytes, and its
expression in B lymphocytes and in epithelial cells precedes
the expression of the lytic cycle antigens associated with virus
replication (Miller, 1990b; Young et al., 1991). However,
BZLF1 expression is not necessarily followed by realisation
of the full lytic cycle. Our results are in agreement with a
report demonstrating BZLF1 expression in an isolated case
of gastric UCNT (Niedobitek et al., 1992a). By contrast, we
have previously demonstrated the absence of the BZLF1
protein from undifferentiated NPC (Niedobitek et al., 1992b).
The detection of the BZLF1 protein in gastric carcinomas is
therefore unexpected and suggests that lytic viral infection
may be possible in undifferentiated epithelial cells and in
epithelial cells showing glandular differentiation.
One of our cases was unusual in that it displayed areas of
EBV-positive gastric UCNT adjacent to areas showing
typical gastric carcinoma without detectable expression of
EBER transcripts. There are at least four possible explana-
tions for this observation: (1) both morphological patterns
might represent a single EBV-positive tumour with very low
levels of EBER transcript expression in those areas showing
typical adenocarcinoma but, whilst heterogenous expression
of the EBER transcripts has been reported (Niedobitek et al.,
1992b) complete absence of this viral gene product from large
areas of an EBV-positive tumour would be unexpected; (2) it
is possible that superinfection of a pre-existing gastric car-
cinoma with EBV has led to the development of an EBV-
positive UCNT; (3) alternatively, loss of EBV from some
UCNT cells with subsequent differentiation into a typical
adenocarcinoma should be considered; (4) this phenomenon
may be the result of the coincidental development of two
independent tumours at the same site. In the absence of
methods for the analysis of the clonality of carcinomas, the
implications of this observation remain uncertain. In the
remaining eight EBV-positive cases, expression of the EBER
transcripts has been demonstrated in virtually all tumour
cells. Moreover, consistent expression of this viral gene prod-
uct has been observed in those cases with multiple tumour
blocks available, including lymph node metastases. This
would suggest that EBV infection was an early event in the
development of these tumours, taking place either before
neoplastic transformation or early in the neoplastic process
providing a growth advantage to the EBV-infected subclone.
EBV is therefore likely to be of pathogenetic significance for
virus-associated gastric carcinomas. The mode of EBV infec-
tion of gastric epithelial cells is unclear. EBV infection of B
lymphocytes occurs via the receptor for the C3d complement
component (C3d/EBV-receptor, CD21 antigen) (Fingeroth et
al., 1984). The possible expression of this molecule in
epithelial cells is still a matter of controversy (Birkenbach et
al., 1992; Niedobitek et al., 1989; Sixbey et al., 1989; Thomas
& Crawford, 1989; Young et al., 1989b). On balance, present
evidence seems to favour the absence of the C3d/EBV-
receptor from epithelial cells. Thus, EBV infection of
epithelial cells is likely to occur by other mechanisms. It
seems reasonable to assume that a common mode of EBV
infection of epithelial cells is employed in the nasopharynx
and in the stomach. Cell fusion between EBV-carrying B
lymphocytes and epithelial cells appears possible (Bayliss &
Wolf, 1980). EBV-harbouring lymphocytes were detected in
approximately 50% of all cases analysed. One might
speculate, therefore, that chronic inflammation of gastric
mucosa leads to increased numbers of EBV-positive lym-
phocytes in the gastric mucosa, thus increasing the likelihood
of fusion events taking place. It has to be stressed, however,
that there is as yet no evidence for the occurrence of fusion
between EBV-positive and EBV-negative cells in vivo. IgA-
mediated infection ofpseudostratified epithelial cells has been
demonstrated in vitro recently (Sixbey & Yao, 1992), and this
mechanism may account for the infection of gastric mucosa.1018 D.C. ROWLANDS et al.
However, both hypotheses would not easily explain the ap-
parent restriction of EBV infection to undifferentiated car-
cinomas of nasopharynx, salivary glands and stomach.
The fact that EBV is detectable in all undifferentiated NPC
and also in all gastric UCNT suggests that EBV infection
may be a rate limiting step for the development of these
tumours. Furthermore, it raises the possibility that EBV
infection somehow prevents differentiation in infected
epithelial cells (Dawson et al., 1990; Fahraeus et al., 1990).
The close association of EBV with gastric UCNT compared
to the variable association with gastric adenocarcinomas sug-
gests fundamentally different roles for the virus in the
aetiology of these two malignancies.
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